Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 13138Triple Negative Breast Neoplasms 1150Neoplasms 750Ovarian Neoplasms 680Neoplasm Metastasis 590Lung Neoplasms 582Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 192Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
TNBC × Breast × Clear all
NCT07622836 2026-06-03

A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase NA Recruiting
59 enrolled
Breast

TNBC

NCT07491822 2026-03-24

A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase NA Not yet recruiting
43 enrolled
Breast

TNBC

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

NCT05918133 2025-03-11

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Biotheus Inc.

Phase 1/2 Active not recruiting
42 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡